29 May 2020
New Data and Society Guidelines Support Value of Oncotype DX Breast Recurrence Score® Test in Guiding Neoadjuvant Treatment Decisions for Newly Diagnosed Patients
14 May 2020
New Oncotype DX Real-world Evidence Shows for the First Time the Practice-changing Impact of TAILORx Results
The Oncotype DX assay has recently been featured in many Canadian national and local newspapers. Below are some stories which may be of interest to you:
British Columbia Breast Cancer Patients Gain Access to Oncotype DX®
New Research Shows Genomic Testing Changes Chemotherapy Treatment Decisions
The Globe and Mail
June 22, 2014
Gene expression profiling test expands to assess colon and prostate cancers -
Article discusses how genomics and the Oncotype DX test can be incorporated in breast, colon and prostate cancer care.
March 8, 2010
Ontario begins funding breast-cancer test
Ontario has begun funding a molecular test that can tell a breast-cancer patient whether they can safely skip chemotherapy.
December 4, 2009
The Oncotype DX cancer test
An overview of the Oncotype DX Breast Cancer Assay from Genomic Health®.
May 07, 2014
Oncotype DX test gives women chemotherapy choice
Global News National
April 13, 2012
Genetic testing prompts new style of preventive health Care
Breast cancer survivor Coree Hanczyk shares her story, explains the role of the Oncotype DX test in her treatment decision.
Global TV Calgary
January 29, 2013
Judge calls for province to fund cancer test
Based on her own breast cancer experience, Alberta patient encourages public funding for genomic testing in the province.
Cancer Research: New Technologies to Know
Could genomic testing be the crystal ball of cancer treatments? Story highlights how the Oncotype DX breast cancer test can help guide chemotherapy treatment decisions.